Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sameer Parekh

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Journal of Virology|May 28, 2003
Genome replication, virion secretion, and e antigen expression of naturally occurring hepatitis B virus core promoter mutantsSameer Parekh, Fabien Zoulim, Sang Hoon Ahn, et al.
Vaccine|December 1, 2012
Antibody persistence of two pentavalent DTwP-HB-Hib vaccines to the age of 15-18 months, and response to the booster dose of quadrivalent DTwP-Hib vaccineHitt Sharma, Sangeeta Yadav, Sanjay Lalwani, et al.
Vaccine|January 11, 2021
A phase-I, open label clinical trial to assess the safety of Tdap vaccine manufactured by Serum Institute of India Pvt. Ltd. in adultsHitt Sharma, K Anil, Sameer Parekh, et al.
Vaccine|October 5, 2011
A phase III randomized, controlled study to assess and compare the immunogenicity and tolerability of single and multi-dose vials of DTwP-Hib, a fully liquid quadravalent vaccine and their comparison with TETRAct-Hib vaccine in Indian infants aged 6-14 weeksHitt Sharma, Sangita Yadav, Vishwanath Patil, et al.
Human Vaccines & Immunotherapeutics|November 22, 2022
A phase I, open label, clinical study to assess the safety and immunogenicity of indigenously developed liquid (DTwP-HepB-IPV-Hib) hexavalent combination vaccine in healthy toddlers aged 16-24 monthsHitt Sharma, Sanjay Lalwani, Sameer Parekh, et al.
Human Vaccines|April 28, 2009
Safety and immunogenicity of an indigenously developed Haemophilus influenzae type b conjugate vaccine through various phases of clinical trialsHitt J Sharma, Amrik S Multani, Ashok K Dutta, et al.
Vaccine: X|May 26, 2023
A phase-I, open label clinical trial to assess the safety & tolerability of qHPV vaccine manufactured by Serum Institute of India Pvt. Ltd. in adultsHitt Sharma, K Anil, Sameer Parekh, et al.
Vaccine|October 12, 2023
Safety and immunogenicity of SIIPL Tdap, a new tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, in healthy subjects 4-65 years of age: A Phase II/III randomized, observer-blinded, active controlled, multicenter clinical study in GermanyInci Aydin, Marcus May, Fabio Pisano, et al.
Frontiers in Immunology|June 21, 2023
Multiplexed bead-based assay for the simultaneous quantification of human serum IgG antibodies to tetanus, diphtheria, pertussis toxin, filamentous hemagglutinin, and pertactinVishal Rathod, Laxmikant Kadam, Manish Gautam, et al.
Vaccine|September 20, 2024
A randomized, active-controlled, multi-centric, phase-II clinical study to assess safety and immunogenicity of a fully liquid DTwP-HepB-IPV-Hib hexavalent vaccine (HEXASIIL®) in Indian toddlersHitt Sharma, Sameer Parekh, Pramod Pujari, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Journal of Virology|May 28, 2003
Genome replication, virion secretion, and e antigen expression of naturally occurring hepatitis B virus core promoter mutantsSameer Parekh, Fabien Zoulim, Sang Hoon Ahn, et al.
Vaccine|December 1, 2012
Antibody persistence of two pentavalent DTwP-HB-Hib vaccines to the age of 15-18 months, and response to the booster dose of quadrivalent DTwP-Hib vaccineHitt Sharma, Sangeeta Yadav, Sanjay Lalwani, et al.
Vaccine|January 11, 2021
A phase-I, open label clinical trial to assess the safety of Tdap vaccine manufactured by Serum Institute of India Pvt. Ltd. in adultsHitt Sharma, K Anil, Sameer Parekh, et al.
Vaccine|October 5, 2011
A phase III randomized, controlled study to assess and compare the immunogenicity and tolerability of single and multi-dose vials of DTwP-Hib, a fully liquid quadravalent vaccine and their comparison with TETRAct-Hib vaccine in Indian infants aged 6-14 weeksHitt Sharma, Sangita Yadav, Vishwanath Patil, et al.
Human Vaccines & Immunotherapeutics|November 22, 2022
A phase I, open label, clinical study to assess the safety and immunogenicity of indigenously developed liquid (DTwP-HepB-IPV-Hib) hexavalent combination vaccine in healthy toddlers aged 16-24 monthsHitt Sharma, Sanjay Lalwani, Sameer Parekh, et al.
Human Vaccines|April 28, 2009
Safety and immunogenicity of an indigenously developed Haemophilus influenzae type b conjugate vaccine through various phases of clinical trialsHitt J Sharma, Amrik S Multani, Ashok K Dutta, et al.
Vaccine: X|May 26, 2023
A phase-I, open label clinical trial to assess the safety & tolerability of qHPV vaccine manufactured by Serum Institute of India Pvt. Ltd. in adultsHitt Sharma, K Anil, Sameer Parekh, et al.
Vaccine|October 12, 2023
Safety and immunogenicity of SIIPL Tdap, a new tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, in healthy subjects 4-65 years of age: A Phase II/III randomized, observer-blinded, active controlled, multicenter clinical study in GermanyInci Aydin, Marcus May, Fabio Pisano, et al.
Frontiers in Immunology|June 21, 2023
Multiplexed bead-based assay for the simultaneous quantification of human serum IgG antibodies to tetanus, diphtheria, pertussis toxin, filamentous hemagglutinin, and pertactinVishal Rathod, Laxmikant Kadam, Manish Gautam, et al.
Vaccine|September 20, 2024
A randomized, active-controlled, multi-centric, phase-II clinical study to assess safety and immunogenicity of a fully liquid DTwP-HepB-IPV-Hib hexavalent vaccine (HEXASIIL®) in Indian toddlersHitt Sharma, Sameer Parekh, Pramod Pujari, et al.
Pageof 3